An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Pluvicto

Chemical Namelutetium (177Lu) vipivotide tetraxetan
Dosage FormInjection (intravenous; 1000 MBq/mL (27 mCi/mL))
Drug ClassRadioactive therapeutic agents
SystemMale reproductive
CompanyAdvanced Accelerator Applications
Approval Year2022

Indication

  • For the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy
Last updated on 4/27/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Pluvicto (lutetium (177Lu) vipivotide tetraxetan) Prescribing Information. 2022Advanced Accelerator Applications USA, Inc., Millburn, NJ
Document TitleYearSource
Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. 2021The New England Journal of Medicine